Beractant
drugOn this page
Also known as A-60386XSurfactant taSurvanta
Summary
Beractant (CHEMBL1201624) is an approved unknown; indicated across 3 conditions including newborn respiratory distress syndrome and acute respiratory distress syndrome.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- Indications: 3 conditions
- Clinical trials: 6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201624 |
| Name | Beractant |
| Type | Unknown |
| Max phase | 4 |
Also known as: A-60386X, Beractant, Surfactant ta, Survanta, BERACTANT
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| newborn respiratory distress syndrome | 4 | MONDO:0700081 | EFO:1000644 |
| acute respiratory distress syndrome | 4 | MONDO:0006502 | EFO:1000637 |
| lung disorder | 4 | MONDO:0005275 | EFO:0003818 |
Clinical trials
Total trials: 6.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 2 |
| PHASE2/PHASE3 | 2 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00767039 | PHASE4 | TERMINATED | Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants |
| NCT01941524 | PHASE4 | COMPLETED | Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations |
| NCT01203358 | PHASE2/PHASE3 | COMPLETED | Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome |
| NCT02774044 | PHASE2/PHASE3 | UNKNOWN | Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates |
| NCT01852461 | Not specified | COMPLETED | Perfusion Index Variability in Respiratory Distress Syndrome |
| NCT01860014 | Not specified | COMPLETED | Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).